Page last updated: 2024-10-28

hydroxychloroquine and Muscular Atrophy, Spinal

hydroxychloroquine has been researched along with Muscular Atrophy, Spinal in 1 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Muscular Atrophy, Spinal: A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Solé, G1
Salort-Campana, E1
Pereon, Y1
Stojkovic, T1
Wahbi, K1
Cintas, P1
Adams, D1
Laforet, P1
Tiffreau, V1
Desguerre, I1
Pisella, LI1
Molon, A1
Attarian, S1

Other Studies

1 other study available for hydroxychloroquine and Muscular Atrophy, Spinal

ArticleYear
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.
    Revue neurologique, 2020, Volume: 176, Issue:6

    Topics: alpha-Glucosidases; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti

2020